Search

Displaying results 6561 - 6570 of 8171 in total
  1. Drug

    Zavacorilant

    go.drugbank.com/drugs/DB21509
    Investigational

    Zavacorilant has a monoisotopic molecular weight of 555.15 Da.

  2. Drug

    Neladalkib

    go.drugbank.com/drugs/DB21712
    Investigational

    Neladalkib has a monoisotopic molecular weight of 452.15 Da.

    Synonyms: an orally bioavailable ALK inhibitor (a macrocyclic compound containing nitrogen heterocycles)
  3. Drug

    Xiliertinib

    go.drugbank.com/drugs/DB21453
    Investigational

    Xiliertinib has a monoisotopic molecular weight of 442.21 Da.

  4. Drug

    Paltimatrectinib

    go.drugbank.com/drugs/DB21588
    Investigational

    Paltimatrectinib has a monoisotopic molecular weight of 434.13 Da.

  5. Drug

    Iptacopan

    go.drugbank.com/drugs/DB16200
    ApprovedInvestigational

    Due to this mutation, all progeny erythrocytes will lack the glycosyl phosphatidylinositol–anchored proteins that normally anchor 2 membrane proteins, CD55 and CD59, that protect blood cells against the

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Substrates
  6. Drug

    Droxidopa

    go.drugbank.com/drugs/DB06262
    ApprovedInvestigational

    The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension.

  7. Drug

    Bacteroides thetaiotaomicron

    go.drugbank.com/drugs/DB17879
    Investigational

    Developed by 4D Pharma, Thetanix, an oral formulation comprising lyophilized Bacteroides thetaiotaomicron, is being investigated for the treatment of Crohn’s disease.[A259892]

  8. Drug

    CYNK-101

    go.drugbank.com/drugs/DB18637
    Investigational

    CYNK-101 is an allogeneic human placental hematopoietic stem cell-derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP).

  9. Drug

    Zandatrigine

    go.drugbank.com/drugs/DB19051
    Investigational

    Zandatrigine is under investigation in clinical trial NCT05226780 (Extension Study to Evaluate How Safe and Tolerable NBI-921352 Is as an Adjunctive Therapy for Participants With SCN8A-DEE).

  10. Drug

    MIP-1095 I-131

    go.drugbank.com/drugs/DB14978
    Investigational

    MIP-1095 I-131 is under investigation in clinical trial NCT03030885 (Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)).